亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

南京肽業(yè)生物科技有限公司多肽  

多肽,氨基酸

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
站內(nèi)搜索
 
榮譽資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產(chǎn)品 > 12279-41-3|絲拉克肽
12279-41-3|絲拉克肽
單價 面議對比
詢價 暫無
發(fā)貨 江蘇付款后3天內(nèi)
品牌 南京肽業(yè)
過期 長期有效
更新 2020-11-05 13:59
 
詳細信息

中文名稱:絲拉克肽

中文同義詞:人ACTH(1-39)肽;絲拉克肽;六氟硅酸;絲拉克肽,≥97%(HPLC)

英文名稱:Seractide

英文同義詞:CORTICOTROPIN(HUMAN);CORTICOTROPHIN;CORTICOTROPINA;H-SER-TYR-SER-MET-GLU-HIS-PHE-ARG-TRP-GLY-LYS-PRO-VAL-GLY-LYS-LYS-ARG-ARG-PRO-VAL-LYS-VAL-TYR-PRO-ASN-GLY-AChemicalbookLA-GLU-ASP-GLU-SER-ALA-GLU-ALA-PHE-PRO-LEU-GLU-PHE-OH;ACTH(1-39)(huMan)Corticotropin;AdrenocorticotropicHormone(ACTH)(1-39);Seractideacetate;AdrenocorticotropicHormone(ACTH)(1-39),human

CAS號:12279-41-3

分子式:C207H308N56O58S1

分子量:4541.07

©2025 南京肽業(yè)生物科技有限公司多肽 版權所有   技術支持:化工網(wǎng)   訪問量:5141  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |